<span lang="EN-GB"></span> <font face="Times New Roman" size="3"> </font> <span lang="EN-GB"></span>

 

 

<span lang="EN-GB"></span>

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

TEST

  • 12/30/2019

    PAION announces submission of New Drug Application for remimazolam by its licensee Hana Pharm in South Korea

  • 11/20/2019

    PAION announces submission of the Marketing Authorization Application for remimazolam in procedural sedation to the European Medicines Agency

  • 11/05/2019

    PAION AG invites to shareholder evening

  • 09/11/2019

    PAION announces attendance at three upcoming conferences

  • 08/22/2019

    Dr. James Phillips appointed to succeed Dr. Wolfgang Söhngen as CEO of PAION AG

  • 08/07/2019

    PAION AG reports financial results for the first half-year of 2019

  • 06/10/2019

    FDA accepts filing of NDA for Remimazolam in the U.S.

  • 05/22/2019

    Annual general Meeting approves all agenda items and elects Dr. Leyck Dieken to the Supervisory Board

  • 03/20/2019

    PAION AG reports on fiscal year 2018

  • 02/07/2019

    PAION AG announces attendance at four upcoming conferences